A-52 Adiponectin for treatments of Ventricular fibrillation and Myocardial infarction
 The effectiveness has already been shown by animal models, pigs.  Adiponectin is an ordinary hormone found in a Human body and safe.
 Can be used during the procedure Could be used with other MI treating medicines
None
Patent Number: US20120035111A1
Application Number: US2010713709A
Inventor: Shibata, Rei | Murohama, Toyoaki
Priority Date: 26 Feb 2010
Priority Number: US20120035111A1
Application Date: 26 Feb 2010
Publication Date: 9 Feb 2012
IPC Current: A61K003816 | A61P000900 | A61P000906 | A61P000910
US Class: 5140164
Assignee Applicant: National University Corporation Nagoya University,Aichi
Title: Therapeutic Application of Adiponectin in Patients with Acute Myocardial Infarction
Usefulness: Therapeutic Application of Adiponectin in Patients with Acute Myocardial Infarction
Summary: The method is useful for treating cardiac diseases in mammals (humans), where the cardiac disease is acute myocardial infarction (all claimed), angina and arrhythmia (ventricular tachycardia, ventricular fibrillation and atrial fibrillation). The ability of adiponectin to treat myocardial infarction (by measuring mortality and incidence of ventricular fibrillation) was tested in pigs. The result showed that the adiponectin-treated pigs exhibited a mortality rate of 0% (i.e. 100% survival) and ventricular fibrillation incidence of 28.6%, when compared to the control-treated pigs that exhibited a mortality rate of 22.2% (77.8% survival) and ventricular fibrillation incidence of 88.9%.
Novelty: Treating cardiac diseases including acute myocardial infarction, angina and arrhythmia (e.g. ventricular tachycardia) in mammals (humans), comprises preparing adiponectin, and administering the adiponectin to the mammal, intracoronarily
Chemical/Material
Chemical/Material Application
USA
